Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA

RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigational therapies that are being studied for the treatment of multiple blood cancers and solid tumors. “The science and data that we will present at ASCO and EHA highlight the breadth and depth of our oncology portfolio and pipeline, and our team’s commitment to advance and deliver innovative treatments for patients,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. “Our research and collaborations underscore a focused scientific strategy to deeply understand disease biology in working towards our ultimate goal of preventing, intercepting and one day curing cancer.” Consistent with ASCO’s theme of Advancing Equitable Cancer Care Through Innovation, Janssen recognizes the importance of eliminating health inequities – from research and clinical trials to access and quality of care – t...

Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news